Pharming Group N.V. (PHAR) stock

PHARNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 2, 2026Score 8/30

$12.95−0.45 (-3.36%)

Close on Nov 12, 2026Market cap $908.68MP/E 323.8Yield –

Pharming gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2025 it was 87.9%, against 88.1% the year before. The highest annual figure on record is 91.5% in fiscal 2022.

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	87.9%	−0.2
FY2024	Dec 31, 2024	88.1%	−1.6
FY2023	Dec 31, 2023	89.7%	−1.7
FY2022	Dec 31, 2022	91.5%	+2.1
FY2021	Dec 31, 2021	89.4%	+0.5
FY2020	Dec 31, 2020	88.9%	+1.5
FY2019	Dec 31, 2019	87.4%	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PHAR.

Revenue growth26.6% · median 38.4%

Gross margin87.9% · median 87.4%

Operating margin6.9% · median -63.0%

Net margin0.8% · median -44.9%

Advertisement
300 × 250

See a number that looks wrong?